Delcath Systems Inc - Company & Market Research Reports

Delcath is a pharmaceutical company with a focus on producing medication for oncology. Their drug Melphalan Hydrochloride with the Delcath Hepatic Delivery System (Melphalan/HDS) is used to deliver high doses of chemotherapy to the liver. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system.


Ocular Cancer Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Ocular Cancer Drug Development Pipeline Review, 2018

  • Report
  • 63 Pages
From
United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices - Product Thumbnail Image

United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

  • Report
  • 980 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018 - Product Thumbnail Image

Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018

  • Report
  • 607 Pages
From
Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 - Product Thumbnail Image

Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

  • Report
  • 330 Pages
From
Hepatocellular Carcinoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatocellular Carcinoma - Pipeline Review, H1 2018

  • Report
  • 1275 Pages
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017

  • Report
  • 766 Pages
From
Hepatocellular Carcinoma - Pipeline Review, H2 2017 - Product Thumbnail Image

Hepatocellular Carcinoma - Pipeline Review, H2 2017

  • Report
  • 1120 Pages
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017

  • Report
  • 609 Pages
From
Liver Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Liver Cancer - Pipeline Review, H2 2016

  • Report
  • 1171 Pages
From
Liver Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Liver Cancer - Pipeline Review, H1 2016

  • Report
  • 1073 Pages
From
Biliary Tumor - Pipeline Insight, 2018 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 506 Pages
From
Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017 - Product Thumbnail Image

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

  • Report
  • 39 Pages
From
Hepatic - Colorectal Metastasis - Pipeline Review, H1 2017 - Product Thumbnail Image

Hepatic - Colorectal Metastasis - Pipeline Review, H1 2017

  • Report
  • 39 Pages
From
Hepatic - Colorectal Metastasis - Pipeline Insight, 2018 - Product Thumbnail Image

Hepatic - Colorectal Metastasis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Uveal Melanoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveal Melanoma - Pipeline Review, H1 2018

  • Report
  • 185 Pages
From
Uveal Melanoma - Pipeline Review, H2 2017 - Product Thumbnail Image

Uveal Melanoma - Pipeline Review, H2 2017

  • Report
  • 155 Pages
From
Metastatic Melanoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Metastatic Melanoma - Pipeline Review, H2 2016

  • Report
  • 648 Pages
From
Uveal Melanoma - Pipeline Insight, 2018 - Product Thumbnail Image

Uveal Melanoma - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Loading Indicator
adroll